Drug Trial Radar · NCT01138514
Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels
Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,555
Actual
Start
Oct 2009
Primary completion
Oct 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Padagis LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).
Conditions
- Acne Vulgaris
Interventions
Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)Drug
Applied to the entire face twice daily for 10 weeks
Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)Drug
Applied to the entire face twice daily for 10 weeks
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Inflammatory LesionsTime frame: 10 weeks
- Percent Change From Baseline in Non-inflammatory LesionsTime frame: 10 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.